- Home
- NTLA vs IRS Comparison
NTLA vs IRS Comparison
Compare NTLA & IRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTLA
- IRS
- Stock Information
- Founded
- NTLA 2014
- IRS 1943
- Country
- NTLA United States
- IRS Argentina
- Employees
- NTLA N/A
- IRS N/A
- Industry
- NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
- IRS Homebuilding
- Sector
- NTLA Health Care
- IRS Real Estate
- Exchange
- NTLA Nasdaq
- IRS Nasdaq
- Market Cap
- NTLA 959.4M
- IRS 1.1B
- IPO Year
- NTLA 2016
- IRS 1994
- Fundamental
- Price
- NTLA $9.53
- IRS $14.56
- Analyst Decision
- NTLA Buy
- IRS Strong Buy
- Analyst Count
- NTLA 18
- IRS 1
- Target Price
- NTLA $50.53
- IRS $12.62
- AVG Volume (30 Days)
- NTLA 3.2M
- IRS 184.8K
- Earning Date
- NTLA 02-20-2025
- IRS 02-11-2025
- Dividend Yield
- NTLA N/A
- IRS 11.32%
- EPS Growth
- NTLA N/A
- IRS N/A
- EPS
- NTLA N/A
- IRS N/A
- Revenue
- NTLA $43,086,000.00
- IRS $370,002,935.00
- Revenue This Year
- NTLA $50.68
- IRS N/A
- Revenue Next Year
- NTLA N/A
- IRS N/A
- P/E Ratio
- NTLA N/A
- IRS N/A
- Revenue Growth
- NTLA N/A
- IRS N/A
- 52 Week Low
- NTLA $9.25
- IRS $7.32
- 52 Week High
- NTLA $34.87
- IRS $17.67
- Technical
- Relative Strength Index (RSI)
- NTLA 36.07
- IRS 41.44
- Support Level
- NTLA $9.93
- IRS $14.30
- Resistance Level
- NTLA $10.73
- IRS $15.70
- Average True Range (ATR)
- NTLA 0.66
- IRS 0.73
- MACD
- NTLA 0.08
- IRS -0.06
- Stochastic Oscillator
- NTLA 13.12
- IRS 12.57
About NTLA Intellia Therapeutics Inc.
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
About IRS IRSA Inversiones Y Representaciones S.A. Global Depositary Shares (Each representing ten shares of)
IRSA Inversiones y Representaciones SA is engaged in a diversified business. The company's operating segment includes Shopping Malls; Offices; Sales and Developments; Hotels and others. It generates maximum revenue from the Shopping Malls segment. The Shopping Malls segment comprised of lease and service revenues related to rental of commercial space and other spaces in the shopping malls of the company.